 |
The Journal of the Japanese Society for Clinical Microbiology |
Biblioraphy Information
| ArticleTitle |
An overview of molecular epidemiology of macrolide-resistant Mycoplasma pneumoniae |
| Language |
J |
| AuthorList |
Yu Suzuki1), Shuichi Abe2) |
| Affiliation |
1) Department of Clinical Laboratory, Yamagata Prefectural Central Hospital
2) Department of Infectious Disease and Infection Control, Yamagata Prefectural Central Hospital |
| Publication |
J.J.C.M.: 30 (3), 117-126, 2020 |
| Received |
May 20, 2020 |
| Accepted |
|
| Abstract |
Mycoplasma pneumoniae is one of the major pathogens that cause upper and lower respiratory tract infections (RTI), such as community-acquired pneumonia, mainly in children and young adults. Macrolides is usually used for the treatment of M. pneumoniae infections as first-line antibiotics; however, the prevalence of RTI due to macrolide-resistant M. pneumoniae has been increasing for these two decades. Macrolide-resistant M. pneumoniae infection has become an important public health concern, and the epidemic of M. pneumoniae infection was observed with high prevalence of macrolide-resistant M. pneumoniae between 2011 and 2012 in Japan. Molecular epidemiological analysis revealed a high prevalence of macrolide resistance in P1 type 1 M. pneumoniae, especially multiple-locus variable-number tandem-repeat analysis (MLVA) type 4-5-7-2, and multi-locus sequence typing (MLST) type ST3 and ST19 strains. The P1 type 1 strain has recently been decreased and the P1 type 2 strain that shows low prevalence of macrolide resistance has been increased, resulting in a decrease of macrolide-resistant M. pneumoniae in Japan. It is necessary for the precise diagnosis of macrolide-resistant M. pneumoniae infection to monitor trends of macrolide resistance in P1 type 2 strain and introduce the genetic testing methods into clinical situation, which should be useful to prepare for future outbreak or epidemic of M. pneumoniae infection. |
| Keywords |
Mycoplasma pneumoniae, MLVA |
|
